Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : SNY save search
Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
sales pipeline sanofi
6 Neuro Data Readouts to Watch in the First Half of 2024
Published: 2024-01-22 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
first
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $14.015 -5.37% -5.67% 140K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 9.45%
H: 0.0%
C: -1.7%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: -1.16%
H: 0.39%
C: -4.31%
sar4435 pharma iph6101 cell results sanofi
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: 1.48%
H: 0.2%
C: -0.33%
rna-1083 covid-19 vaccine positive influenza
Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Published: 2023-08-14 (Crawled : 05:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
momentum program
Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma
Published: 2023-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
publication therapeutics
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-07-11 (Crawled : 06:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
iph6401 trial
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: 1.84%
H: 6.63%
C: 4.82%
pharma results study phase 2
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
Published: 2023-05-26 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 1.67%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: 1.04%
H: 1.54%
C: -0.51%
iph6101 pharma cell aml sanofi
Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
potential
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Published: 2022-11-04 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.25%
H: 0.11%
C: -1.03%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: -4.27%
H: 8.9%
C: 6.93%
pharma trial results platform
TrialSpark and Sanofi Ink Six-Drug Deal Targeting Areas with High Unmet Need (Updated)
Published: 2022-10-05 (Crawled : 22:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
deal sanofi
FDA Action Alert: Amylyx's Moment of Truth and Dupixent Seeks another Nod
Published: 2022-09-26 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
fda dupixent
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
Published: 2022-07-27 (Crawled : 15:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
promise
Myrtelle's Investigational Canavan Disease Treatment Shows Early Promise
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -0.15%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
treatment disease promise
Innate's Cancer Therapeutics are Reaching New Clinical Heights
Published: 2022-07-04 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
therapeutics cancer
COVID-19 Vaccine Leaders Make Progress on Omicron-Specific Boosters
Published: 2022-06-27 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
covid-19 vaccine
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 vaccine trial results topline
Can Olema Oncology Prevail Where Other SERDs have Recently Failed?
Published: 2022-06-21 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.92%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.